BADAL X: 5-year follow-up on performance and safety
Dr. R. Atallah et al., in ‘Bone and Joint Journal’, April 2025
A single-center study at the Radboud University Medical Center in the Netherlands
Results
- Implant survival: 94.2%
- Performance: Prosthesis use improved by 58%,
Quality of life (QTFA total score) improved by 68%.
Patient group
69 people with transfemoral amputations and 21 people with transtibial amputations
Including:
13% of people with a dysvascular amputation cause
53 people received a standard femoral stem (2 bilaterally)
16 people received a short femoral stem (1 bilaterally)
21 people received a tibial stem (1 bilaterally)
Statistics
Comparison of implant survival rates of bone anchorage systems in the EU:
BADAL X (OTN Implants, NL): 94.2% (this study; Atallah et al., BJJ, 2025)
OPRA (Integrum, SE): 92% (Branemark et al., J Am Acad Orthop Surg, 2019)
Endo Exo (Eska/Orthodynamics, DE): 90% (Reetz et al., JBJS Am, 2020)
Improving prosthetic use:
58% (52.7 points at baseline with stem prosthesis, up to 83.4 points after 5 years of FU with BADAL X)
Improvement in quality of life (QTFA total score):
68% (39.5 points at baseline with stem prosthesis, up to 66.6 points after 5 years of FU with BADAL X)